Cardiologists’ Expectations of Aortic Valvuloplasty

  • Hiroyuki WatanabeEmail author


In recent years, aortic stenosis and mitral regurgitation have stolen the limelight from other forms of valvular disease. However, treatment of aortic regurgitation (AR) has made solid advancements, of which the greatest have been the improved outcomes for aortic valvuloplasty, which has already become a practical option in a few institutions.


  1. 1.
    Boodhwani M, de Kerchove L, Glineur D, Poncelet A, Rubay J, Astarci P, et al. Repair-oriented classification of aortic insufficiency: impact on surgical techniques and clinical outcomes. J Thorac Cardiovasc Surg. 2009;137:286–94.CrossRefGoogle Scholar
  2. 2.
    Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, et al., PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014;147:1202–10.CrossRefGoogle Scholar
  3. 3.
    Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al., RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.Google Scholar
  4. 4.
    Isaacs AJ, Shuhaiber J, Salemi A, Isom OW, Sedrakyan A. National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements. J Thorac Cardiovasc Surg. 2015;149:1262–9.e3.CrossRefGoogle Scholar
  5. 5.
    Chan V, Malas T, Lapierre H, Boodhwani M, Lam BK, Rubens FD, et al. Reoperation of left heart valve bioprostheses according to age at implantation. Circulation. 2011;124:S75–80.CrossRefGoogle Scholar
  6. 6.
    Urso S, Calderón P, Sadaba R, Mahillo I, Tuñón J, Aldamiz G, et al. Patient-prosthesis mismatch in patients undergoing bioprosthetic aortic valve implantation increases risk of reoperation for structural valve deterioration. J Card Surg. 2014;29:439–44.CrossRefGoogle Scholar
  7. 7.
    Johnston DR, Soltesz EG, Vakil N, Rajeswaran J, Roselli EE, Sabik JF 3rd, et al. Long-term durability of bioprosthetic aortic valves: implications from 12,569 implants. Ann Thorac Surg. 2015;99:1239–47.CrossRefGoogle Scholar
  8. 8.
    McClure RS, McGurk S, Cevasco M, Maloney A, Gosev I, Wiegerinck EM, et al. Late outcomes comparison of nonelderly patients with stented bioprosthetic and mechanical valves in the aortic position: a propensity-matched analysis. J Thorac Cardiovasc Surg. 2014;148:1931–9.CrossRefGoogle Scholar
  9. 9.
    Mérie C, Køber L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA. 2012;308:2118–25.CrossRefGoogle Scholar
  10. 10.
    Berger PB, Vedamurthy D, Casale A, Sun H, Benoit C, Ferrari A, et al. The risk of thromboembolic complications without anticoagulation after surgical aortic valve replacement with a bioprosthesis. J Am Coll Cardiol. 2015;65:A2041. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Cardiology, Cardiac CenterTokyo Bay Urayasu Ichiwaka Medical CenterUrayasuJapan

Personalised recommendations